Table 2: Imaging and pathological data of study subjects.

PatientAge (y) GenderCT resultNP-59 resultPathological resultFollowup improvement
Appearance (side)Size (mm)PlanarSPECTSPECT/CTFindingSize (mm)

Control group (n = 9)
150FNodule (L)20Adenoma21PAC, PRA, K
234FNodule (L)18Adenoma16PAC, PRA, K, BP
358FNodule (R)17Adenoma17PAC, PRA, K
432FNodule (L)20Adenoma20PAC, K, BP
571FNodule (L)17Adenoma25PAC, PRA, K, BP
659MNodule (L)11Adenoma10PAC, BP
760FNodule (R)21Adenoma20PAC, K
872MNodule (R)22Adenoma20PAC, PRA, K, BP
956FNodule (L)17Adenoma17PAC, K, BP

SPECT/CT group (n = 6)
1055FNormalNRRMicronodule0.8PAC, K, BP
1148FNodule (L)17LLLAdenoma17PAC, PRA, K, BP
1257MEnlarge (L)9 (in thickness)NLLFocal nodular hyperplasia6PAC, PRA, K, BP
1356MNodule (L)12NLLAdenoma10PAC, BP
1439MNodule (R)14NRRAdenoma12PAC, K, BP
1527FNormalFaintBilBil##PAC, BP

Abbreviations: CT: computed tomography; L: left; R: right; Bil: bilateral; other abbreviations are the same as Table 1.
Patients 12 and 15 had stages 3 and 4 chronic kidney disease with serum creatinine level of 2.2 and 2.5 mg/dL, respectively.
#Patient 15 did not undergo adrenalectomy because of bilateral adrenal hyperplasia.